Viewing Company Abbott Labs | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

Abbott Labs Stock Symbol: ABT-N

Last Price Recorded: $38.1000 on 2016-05-04

Globe 5 day average
Google Discussions (view only)
yahoo discussion
Bloomberg
Date Signal Expert Opinion Price
2013-05-31 BUY Gavin Graham

One of the better ways to play pharmaceuticals. Amongst the big Pharmas it is one of the few that actually held up through the big selloff of the patent expiries in the mid-2000. Has a yield of about 2%.


Price:
$36.670
Subject:
NORTH AMERICAN/GLOBAL
Bias:
UNKNOWN
Owned:
Yes
2013-05-09 PAST TOP PICK David Burrows

(Top Pick May 17/12, Up 24.24%) He stayed with this and not the spin-out.  This is about the best performing part of the market this year.  Good dividend growth and very strong balance sheets. 


Price:
$36.180
Subject:
NORTH AMERICAN - LARGE
Bias:
SELECTIVE
Owned:
Yes
2013-04-15 PAST TOP PICK Gavin Graham

(A Top Pick March 15/12. Up 33.59%.) Excellent stock that has done really well. Dividend yield.


Price:
$36.130
Subject:
GLOBAL
Bias:
OPTIMISTIC
Owned:
Yes
2013-04-09 BUY Christine Poole

Split off into 2 companies. This one and Abbvie (ABBV-N). Sold her holdings just before the split and wanted to get back in to this one, which was their pharmaceutical side. The other was too reliant on one drug. This is in nutrition, medical devices and branded generics. Have very big emerging-market exposure. Thinks there is big growth in branded generics. Dividend of just under 2%. Her target is high $30’s-$40 in one year.


Price:
$36.660
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Yes
2013-03-07 BUY Patrick Horan

Just initiated 3.6% dividend.  Does like it.  They may put growth back into business model or you have an activist shareholder that puts them up for sale.  If stock stays flat you will collect the divided.


Price:
$34.430
Subject:
NORTH AMERICAN
Bias:
BULL
Owned:
Yes
2013-02-26 COMMENT Barry Schwartz

Split into 2 companies, this one and Abbvie (ABBV-N).He is not sold entirely on the split although he continues to hold both. On this one you get the nutritionals, some pharmaceuticals and medical devices. Valuation is not as attractive as it was before the split.


Price:
$34.060
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
Yes
2013-02-25 BUY Chyanne Fickes

She sold ABv.  But ABT-N has a very good basic business.  Doesn’t understand why they don’t pay more dividend (1.6%) and thinks they may increase it soon. 


Price:
$34.270
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Yes
2013-02-12 TOP PICK Christine Poole

Diversified. Have nutritionals, diagnostics (nice solid business), branded generics and medical devices where they have the leading drug eluting stents. 40% of sales are coming from high-growth emerging markets. Room for margin expansion. 1.64% dividend.


Price:
$34.300
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Yes
2013-02-05 COMMENT John O'Connell, CFA

(Market Call Minute.) There is a spinoff coming on a restructuring, so be careful about tax implications. When it spins off, buy the medical device manufacturer.


Price:
$33.840
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Unknown
2013-01-10 HOLD Gordon Reid

Had a spinoff of their pharmaceutical side and this company now just represents the diagnostic and nutritional business. If you own, wait and see how things settle out for them.


Price:
$33.850
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
No
2012-12-03 BUY Barry Schwartz

It already had a bump up in price, but he is planning on holding both parts.  Buying for new clients.


Price:
$64.290
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Yes
2012-11-30 TOP PICK Chyanne Fickes

Splitting as of Jan 2nd.  Trading ‘as is’ in December.  ‘New Abbot’ is their nutritional, diagnostics, vascular and diversified business, very solid sales outlooks.  Thinks there is more upside in the Drug exploration part.  Humera is one of the 5 biggest drugs globally.  5 drugs in clinical trials.  A really good pipeline. 


Price:
$65.000
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Yes
2012-11-26 TOP PICK Brian Acker, CA

You can buy at its model price and when the company splits up it would increase value.  The balance sheet has high growth parts buried within it.  These smaller parts create more value.  The pieces are worth more than the whole.  40 increases in dividends and very shareholder friendly.  He would stay with both after the split until you can review balance sheets.


Price:
$64.360
Subject:
NORTH AMERICAN - LARGE
Bias:
SELECTIVE
Owned:
Yes
2012-11-21 SELL Gordon Reid

(Market Call Minute) Would sell on the split.  It is too complicated to be there with the split.


Price:
$63.330
Subject:
US EQUITIES
Bias:
SELECTIVE
Owned:
Unknown
2012-11-19 TOP PICK Mohsin Bashir

12 drugs under patent after a current one comes off patent.  A hepatitis drug is about to come out as well.  It could hit its 52 week high.


Price:
$62.920
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
Yes
Showing 31 to 45 of 92 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.